Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Acquisitions & Divestments (2017 - 2025)

Historic Change in Acquisitions & Divestments for Editas Medicine (EDIT) over the last 9 years, with Q3 2025 value amounting to $40.0 million.

  • Editas Medicine's Change in Acquisitions & Divestments fell 5396.32% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.5 million, marking a year-over-year decrease of 4811.24%. This contributed to the annual value of $257.2 million for FY2024, which is 89.25% down from last year.
  • Latest data reveals that Editas Medicine reported Change in Acquisitions & Divestments of $40.0 million as of Q3 2025, which was down 5396.32% from $42.5 million recorded in Q2 2025.
  • Editas Medicine's 5-year Change in Acquisitions & Divestments high stood at $130.8 million for Q1 2021, and its period low was $31.5 million during Q4 2024.
  • Over the past 5 years, Editas Medicine's median Change in Acquisitions & Divestments value was $74.2 million (recorded in 2021), while the average stood at $76.4 million.
  • In the last 5 years, Editas Medicine's Change in Acquisitions & Divestments skyrocketed by 17647.87% in 2021 and then plummeted by 6939.36% in 2024.
  • Over the past 5 years, Editas Medicine's Change in Acquisitions & Divestments (Quarter) stood at $84.3 million in 2021, then fell by 6.91% to $78.5 million in 2022, then soared by 31.08% to $102.9 million in 2023, then tumbled by 69.39% to $31.5 million in 2024, then increased by 27.03% to $40.0 million in 2025.
  • Its last three reported values are $40.0 million in Q3 2025, $42.5 million for Q2 2025, and $56.5 million during Q1 2025.